DOI: 10.11958/20161460
The progress of clinical precision medicine in castration-resistant prostate cancer
WANG Hai-tao
Abstract：Most prostate cancer (PCa) patients in China are diagnosed at an advanced stage. Many PCa patients are initially sensitive to hormonal therapy and experience temporary tumor regression, but nearly all of the patients finally reach a state of castration-resistant prostate cancer (CRPC). CRPC is difficult to cure and thus has poor prognosis. The identification of new therapies to treat CRPC remains an urgent need. Precision medicine is to develop the most appropriate individualized treatment for each patient based on the level of individual differences. Genomic, proteomics, metabolomics data, and other big data analysis methods are the essence of precision medicine. Precision medicine brings the hope to overcome cancer. In this review, we summarize the connotation of precision medicine in CRPC, the application of second generation sequencing and genome sequencing, and clinical molecular targeted therapy of CRPC as well as discuss clinical precision medicine for CRPC.
Keywords：genestumor suppressorgene therapycomputational biologyreviewcastration-resistant prostate cancerprecision medicineindividualized treatmentmolecular targeted therapy
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 337-341 )